Axogen, Inc.

It out-grows 89% of companies worldwide.

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 22%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 18%/yr over the last 3 years and is set to grow 22%/yr from here.

The runway holds up: revenue is set to grow 21%/yr over five years.9/10

None flagged.

The company is loss-making, so its revenue growth is not backed by profit yet.

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

Magnificent long-term results. Long-term holders have seen +687% over three years and +152% over five, ahead of 80% of the market.

It's up 110% over the past year, but 32% below its 52-week high. That is clearly ahead of the market.

Returns sit at the market level so far this year (+10%).

The stock is underperforming over the past month (-23%) and over three months (-16%).

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over the past month and over three months.